Truist raised the firm’s price target on Edgewise Therapeutics (EWTX) to $50 from $33 and keeps a Buy rating on the shares. The firm has greater conviction in the potential for share upside based on due diligence, management commentary, positive KOL feedback, and expectations for data readouts in bone mineral density and hypertrophic cardiomyopathy, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics initiated with an Outperform at Evercore ISI
- Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials
- Edgewise Therapeutics reports Q3 EPS (36c), consensus (37c)
- Edgewise Therapeutics call volume above normal and directionally bullish
- Edgewise Therapeutics price target raised to $51 from $48 at Piper Sandler